A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT07244341)
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Who can join: Review the eligibility criteria below.
Location: University of California San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- University of California San Diego Moores Cancer Center — La Jolla, California
- Beth Isreal Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Newton, Massachusetts
- Cancer & Hematology Center — Grand Rapids, Michigan
- Northwell Health Cancer Institute (START NY) — Lake Success, New York
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- NEXT Oncology — San Antonio, Texas
- Virginia Cancer Specialists (NEXT Virginia) — Fairfax, Virginia
- Medical College Of Wisconsin — Milwaukee, Wisconsin
- Sun Yatsen University Cancer Center — Guangzhou,
- Fudan University Shanghai Cancer Center - Xuhui District — Shanghai,
- Fudan University Shanghai Cancer Center — Shanghai,
- Shanghai General Hospital — Shanghai,
- The First Affiliated Hospital of Wenzhou Medical University — Wenzhou,
- Mater Misericordiae University Hospital — Dublin,
- National Cancer Center Hospital East — Kashiwa-shi,
- Kobe City Med Cen Gen Hosp. — Kobe,
- Cancer Institute Hospital of JFCR — Kōtoku,
- Toho University Sakura Medical Center — Sakura-shi,
📞 Contact the Study Coordinator
Phone: (908) 992-6400
Email: CTRinfo_us@daiichisankyo.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.